Skip to content

Application Value of Nutritional Screening in Mild Hepatic Encephalopathy Associated with Small Intestine Bacterial Overgrowth of Liver Cirrhosis

Application Value of Nutritional Screening in Mild Hepatic Encephalopathy Associated with Small Intestine Bacterial Overgrowth of Liver Cirrhosis

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200055582
Enrollment
Unknown
Registered
2022-01-14
Start date
2022-01-15
Completion date
Unknown
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild hepatic encephalopathy

Interventions

Case group:Nutritional risk score
Control group:Nutritional risk score

Sponsors

Affiliated Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
32 Years to 78 Years

Inclusion criteria

Inclusion criteria: 1.Patients with liver cirrhosis were diagnosed according to the 2019 guidelines for the diagnosis and treatment of liver cirrhosis.

Exclusion criteria

Exclusion criteria: 1. Patients with brain diseases such as cerebral hemorrhage, cerebral infarction, brain tumor, intracranial infection, epilepsy, metabolic encephalopathy such as ketoacidosis, hypoglycemia, renal encephalopathy, pulmonary encephalopathy, alcoholic encephalopathy, heavy metal toxic encephalopathy, abstinence syndrome and other toxic encephalopathy; 2. A patient with a history of mental illness; 3. Patients with dominant hepatic encephalopathy or previous history of dominant hepatic encephalopathy; 4. Patients with diabetes, severe cardiopulmonary disease, renal insufficiency, thyroid disease, intestinal obstruction, etc. other extrahepatic diseases that can lead to malnutrition and chronic diarrhea; patients with a history of gastrointestinal bleeding within 6 weeks; patients with persistent active infection; 5. Patients who had received Helicobacter pylori sterilization or antibiotics, lactulose, probiotics, PPI and gastrointestinal motility drugs such as mosapride and domperidone within two weeks; patients who had been tested by enema or colonoscopy within 1 month; 6. Patients who have undergone abdominal surgery such as gastrectomy and enterectomy; 7. Patients with hearing and visual impairment that are unable to undergo digital connection test and digital symbol test; 8. Patients with poor compliance and other factors that may affect the results of this experiment.

Design outcomes

Primary

MeasureTime frame
nutritional risk score;Blood sugar;Protein determination;Blood lipid analysis;Electrolyte determination;MELD score;

Countries

China

Contacts

Public ContactCao Bin

Qingdao University

qycaobin@126.com+86 18661806527

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026